vs
Side-by-side financial comparison of ASTROTECH Corp (ASTC) and BIO-RAD LABORATORIES, INC. (BIO). Click either name above to swap in a different company.
BIO-RAD LABORATORIES, INC. is the larger business by last-quarter revenue ($693.2M vs $148.0K, roughly 4683.8× ASTROTECH Corp). BIO-RAD LABORATORIES, INC. runs the higher net margin — 103.9% vs -2653.4%, a 2757.2% gap on every dollar of revenue. On growth, BIO-RAD LABORATORIES, INC. posted the faster year-over-year revenue change (3.9% vs -43.3%). BIO-RAD LABORATORIES, INC. produced more free cash flow last quarter ($119.1M vs $-4.0M). Over the past eight quarters, ASTROTECH Corp's revenue compounded faster (72.0% CAGR vs 6.5%).
Astrotech Corporation, formerly Spacehab Inc., is a technology incubator headquartered in Austin, Texas. Astrotech uses technology sourced internally and from research institutions, government laboratories, and universities to fund, manage and sell start-up companies. Astrotech Corporation's subsidiaries provide commercial products and services to NASA, the U.S. Department of Defense, national space agencies, and global commercial customers.
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets. The company was founded in 1952 in Berkeley, California, by husband and wife team David and Alice Schwartz, both graduates of the University of California, Berkeley. Bio-Rad is based in Hercules, California, and has operations worldwide.
ASTC vs BIO — Head-to-Head
Income Statement — Q2 2026 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $148.0K | $693.2M |
| Net Profit | $-3.9M | $720.0M |
| Gross Margin | 5.4% | 49.8% |
| Operating Margin | -2635.8% | -17.2% |
| Net Margin | -2653.4% | 103.9% |
| Revenue YoY | -43.3% | 3.9% |
| Net Profit YoY | 2.0% | 200.6% |
| EPS (diluted) | — | $26.59 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $148.0K | $693.2M | ||
| Q3 25 | $297.0K | $653.0M | ||
| Q2 25 | $220.0K | $651.6M | ||
| Q1 25 | $534.0K | $585.4M | ||
| Q4 24 | $261.0K | $667.5M | ||
| Q3 24 | $34.0K | $649.7M | ||
| Q2 24 | $74.0K | $638.5M | ||
| Q1 24 | $50.0K | $610.8M |
| Q4 25 | $-3.9M | $720.0M | ||
| Q3 25 | $-3.5M | $-341.9M | ||
| Q2 25 | $-2.9M | $317.8M | ||
| Q1 25 | $-3.6M | $64.0M | ||
| Q4 24 | $-4.0M | $-715.8M | ||
| Q3 24 | $-3.3M | $653.2M | ||
| Q2 24 | $-3.0M | $-2.2B | ||
| Q1 24 | $-3.2M | $383.9M |
| Q4 25 | 5.4% | 49.8% | ||
| Q3 25 | 63.3% | 52.6% | ||
| Q2 25 | 33.6% | 53.0% | ||
| Q1 25 | 44.4% | 52.3% | ||
| Q4 24 | 59.4% | 51.2% | ||
| Q3 24 | 26.5% | 54.8% | ||
| Q2 24 | 37.8% | 55.6% | ||
| Q1 24 | 16.0% | 53.4% |
| Q4 25 | -2635.8% | -17.2% | ||
| Q3 25 | -1190.6% | 10.0% | ||
| Q2 25 | -1326.4% | 11.8% | ||
| Q1 25 | -724.2% | 4.0% | ||
| Q4 24 | -1655.6% | 8.7% | ||
| Q3 24 | -10670.6% | 9.9% | ||
| Q2 24 | -4518.9% | 15.9% | ||
| Q1 24 | -7066.0% | 7.3% |
| Q4 25 | -2653.4% | 103.9% | ||
| Q3 25 | -1166.7% | -52.4% | ||
| Q2 25 | -1331.8% | 48.8% | ||
| Q1 25 | -680.3% | 10.9% | ||
| Q4 24 | -1536.0% | -107.2% | ||
| Q3 24 | -9641.2% | 100.5% | ||
| Q2 24 | -3998.6% | -339.2% | ||
| Q1 24 | -6308.0% | 62.9% |
| Q4 25 | — | $26.59 | ||
| Q3 25 | — | $-12.70 | ||
| Q2 25 | — | $11.67 | ||
| Q1 25 | — | $2.29 | ||
| Q4 24 | — | $-25.89 | ||
| Q3 24 | — | $23.34 | ||
| Q2 24 | — | $-76.26 | ||
| Q1 24 | — | $13.45 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $1.5B |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $15.5M | $7.5B |
| Total Assets | $19.7M | $10.6B |
| Debt / EquityLower = less leverage | — | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $1.5B | ||
| Q3 25 | $11.3M | $1.4B | ||
| Q2 25 | $15.1M | $1.4B | ||
| Q1 25 | $18.1M | $1.7B | ||
| Q4 24 | $21.5M | $1.7B | ||
| Q3 24 | $21.8M | $1.6B | ||
| Q2 24 | $42.9M | $1.6B | ||
| Q1 24 | $52.4M | $1.6B |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $15.5M | $7.5B | ||
| Q3 25 | $19.1M | $6.7B | ||
| Q2 25 | $22.1M | $7.1B | ||
| Q1 25 | $24.8M | $6.7B | ||
| Q4 24 | $28.1M | $6.6B | ||
| Q3 24 | $32.1M | $7.5B | ||
| Q2 24 | $34.8M | $6.8B | ||
| Q1 24 | $37.6M | $9.1B |
| Q4 25 | $19.7M | $10.6B | ||
| Q3 25 | $23.2M | $9.7B | ||
| Q2 25 | $27.0M | $10.2B | ||
| Q1 25 | $27.5M | $9.5B | ||
| Q4 24 | $31.0M | $9.4B | ||
| Q3 24 | $34.4M | $10.6B | ||
| Q2 24 | $37.6M | $9.7B | ||
| Q1 24 | $40.2M | $12.6B |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.18× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.18× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-3.5M | $164.9M |
| Free Cash FlowOCF − Capex | $-4.0M | $119.1M |
| FCF MarginFCF / Revenue | -2671.6% | 17.2% |
| Capex IntensityCapex / Revenue | 277.7% | 6.6% |
| Cash ConversionOCF / Net Profit | — | 0.23× |
| TTM Free Cash FlowTrailing 4 quarters | $-14.9M | $374.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-3.5M | $164.9M | ||
| Q3 25 | $-3.9M | $120.9M | ||
| Q2 25 | $-2.4M | $116.5M | ||
| Q1 25 | $-3.9M | $129.9M | ||
| Q4 24 | $-3.0M | $124.2M | ||
| Q3 24 | $-3.7M | $163.6M | ||
| Q2 24 | $-2.5M | $97.6M | ||
| Q1 24 | $-2.3M | $69.8M |
| Q4 25 | $-4.0M | $119.1M | ||
| Q3 25 | $-4.4M | $89.2M | ||
| Q2 25 | $-2.7M | $70.8M | ||
| Q1 25 | $-3.9M | $95.5M | ||
| Q4 24 | $-3.4M | $81.2M | ||
| Q3 24 | $-3.9M | $123.4M | ||
| Q2 24 | $-2.8M | $55.4M | ||
| Q1 24 | $-2.5M | $29.6M |
| Q4 25 | -2671.6% | 17.2% | ||
| Q3 25 | -1476.1% | 13.7% | ||
| Q2 25 | -1231.4% | 10.9% | ||
| Q1 25 | -728.1% | 16.3% | ||
| Q4 24 | -1288.5% | 12.2% | ||
| Q3 24 | -11408.8% | 19.0% | ||
| Q2 24 | -3728.4% | 8.7% | ||
| Q1 24 | -5036.0% | 4.8% |
| Q4 25 | 277.7% | 6.6% | ||
| Q3 25 | 150.8% | 4.9% | ||
| Q2 25 | 158.2% | 7.0% | ||
| Q1 25 | 5.1% | 5.9% | ||
| Q4 24 | 122.2% | 6.4% | ||
| Q3 24 | 567.6% | 6.2% | ||
| Q2 24 | 305.4% | 6.6% | ||
| Q1 24 | 352.0% | 6.6% |
| Q4 25 | — | 0.23× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | — | 2.03× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.25× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.18× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ASTC
Segment breakdown not available.
BIO
| Clinical Diagnostics | $425.3M | 61% |
| Life Science | $267.9M | 39% |
